TIDMGDR
Genedrive PLC
13 March 2018
For release: 13 March 2018
genedrive plc ("genedrive" or the "Company")
Commercial sales of Genedrive(R) HCV ID Kit and platform
begin
Decentralised molecular HCV assays shipped to Africa
genedrive plc (AIM: GDR), the near patient molecular diagnostics
company, today announces that is has commenced commercial sales and
shipments of its Genedrive(R) HCV ID Kit and Genedrive(R) platform
into the EMEA region. The products have been shipped to genedrive's
distributor, Sysmex Corporation ("Sysmex"), a world leader in
clinical laboratory systemization and solutions, and are now
destined for use in various initial target countries. In addition,
first commercial sales and shipments of the Genedrive(R) HCV ID Kit
and Genedrive(R) platform are expected to commence in the Asia
Pacific region in the coming weeks.
David Budd, Chief Executive Officer of genedrive plc, said:
"Since signing our distribution agreements with Sysmex, we have
continued to build momentum in the market and we are pleased to see
initial commercial sales. An ongoing process of registering the
products in target countries will naturally lead to a growing
opportunity, and we are confident that as the first to market
decentralised qualitative molecular HCV test, Genedrive(R) is
uniquely positioned to meet this need."
With the advent of new 'curative' direct acting antiviral
treatments for Hepatitis C (HCV), genedrive and Sysmex believe that
there is a major opportunity to support tackling the global burden
of the disease if accurate, decentralised diagnostics can be used
to identify those living with HCV and give them access to therapy.
These first sales mark a further important step towards that
goal.
The Genedrive(R) HCV ID Kit, a qualitative molecular assay for
HCV has received CE-IVD Certification from the EU. Recently
announced field study results demonstrated the robust performance
of the HCV test in a third party setting and on samples from
sub-Saharan Africa with demonstrated sensitivity and specificity of
100% compared to the Abbott M2000 HCV Real time assay as a
reference. The test also demonstrated efficiency of 95.4% (result
achieved at first attempt).
genedrive plc has signed a distribution agreement with Sysmex
Europe GmbH, a subsidiary of Sysmex Corporation, for the
Genedrive(R) HCV ID Kit and Genedrive(R) platform in the EMEA
region with an initial focus on Africa. genedrive plc has also
entered into a distribution agreement with Sysmex Asia Pacific Pte
Ltd, a subsidiary of Sysmex Corporation, for its CE-marked
Genedrive(R) HCV ID Kit and Genedrive(R) platform in the Asia
Pacific region.
- Ends -
For further details please contact:
genedrive plc
David Budd: CEO +44 (0)161 989 0245
Matthew Fowler: CFO
Peel Hunt LLP
James Steel +44 (0)207 418 8900
Oliver Jackson
Consilium Strategic Communications
Chris Gardner +44 (0)203 709 5700
Matthew Neal
Laura Thornton
genedrive@consilium-comms.com
Notes to Editors
About genedrive plc
genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need molecular diagnostics platform for the
diagnosis of infectious diseases and for use in patient
stratification (genotyping), pathogen detection and other
indications. The Genedrive(R) platform and MTB/RIF assay has been
launched in India and a Genedrive(R) HCV test has received CE-IVD
Certification and has been launched in Africa. genedrive has
distribution agreements with subsidiaries of Sysmex Corporation for
the distribution of the Genedrive(R) platform in the EMEA and Asia
Pacific regions.
Further details can be found at: www.genedriveplc.com and
www.genedrive.com
About Sysmex Europe
Sysmex Europe GmbH (SEG), located near Hamburg, Germany, is a
subsidiary of the Sysmex Corporation from Kobe, Japan. From our
Hamburg offices - designated a Great Place to Work(R) in 2014 and
2016 - we serve our affiliates, distributors and customers
throughout EMEA - Europe, the Middle East and Africa. Globally we
employ around 8000 staff, of whom 1300 work in the EMEA region.
Sysmex is the global leader in haematology and a renowned
specialist in haemostasis, urinalysis, and laboratory automation.
As our expertise in the interdependency of disease and medical
disciplines grows, we are growing to cover other pressing areas
such as oncology, flow cytometry, liquid biopsy and essential
healthcare in resource-poor regions. This is allowing us to deliver
clinical value that primary healthcare workers such as physicians,
surgeons and other specialists can use directly to deliver better
diagnostics, treatment and monitoring, and so improve the quality
of life of their patients.
Everything we do is driven by a single mission: Shaping the
advancement of healthcare.
For more information about Sysmex Europe, please visit
www.sysmex-europe.com, and for details on Sysmex Africa
www.sysmex.co.za
About Hepatitis C
Hepatitis C (HCV) is an international public health challenge,
comparable to other major communicable diseases, including HIV,
tuberculosis and malaria. It is estimated that 150-200 million
people, or approximately 3% of the world's population, are living
with chronic HCV, and more than 350,000 people die yearly from
HCV-related diseases. In 2016, WHO published the first global
health sector strategy on Hepatitis with a goal of eliminating
viral hepatitis as a major public health threat by 2030. New oral,
well-tolerated treatment regimens can achieve cure rates of over
90%, however, access to rapid, inexpensive and accurate diagnostics
are a critical bottleneck that must be addressed to eradicate
HCV.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAJTMTTMBABTAP
(END) Dow Jones Newswires
March 13, 2018 03:02 ET (07:02 GMT)
Epistem (LSE:EHP)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Epistem (LSE:EHP)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024